A prospective cohort of newly diagnosed DLBCL patients treated with RCHOP demonstrated that TP53 mutations are correlated with disease progression and poor survival and survival analysis for patients with wild-type TP53 had significantly better OS (P =0.0041) and PFS (P =0.0084) [33]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.